Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2026)

Contineum Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $16.9 million for Q1 2026.

  • Quarterly Operating Expenses fell 6.66% to $16.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $66.9 million through Mar 2026, up 13.17% year-over-year, with the annual reading at $68.1 million for FY2025, 33.73% up from the prior year.
  • Operating Expenses came in at $16.9 million for Q1 2026, down from $17.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $18.1 million in Q1 2025 to a low of $5.1 million in Q1 2023.
  • The 4-year median for Operating Expenses is $13.0 million (2024), against an average of $13.1 million.
  • Year-over-year, Operating Expenses skyrocketed 94.13% in 2024 and then decreased 6.66% in 2026.
  • Contineum Therapeutics' Operating Expenses stood at $9.7 million in 2023, then soared by 76.18% to $17.0 million in 2024, then increased by 0.4% to $17.1 million in 2025, then decreased by 1.23% to $16.9 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Operating Expenses are $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $14.9 million (Q3 2025).